FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2078751312> ?p ?o ?g. }

• W2078751312 endingPage "140" @default.
• W2078751312 startingPage "131" @default.
• W2078751312 abstract "Bacillus Calmette-Guérin (BCG) is a standard treatment for reducing tumour recurrence and delaying progression of high-risk non-muscle-invasive bladder tumours. However, it is not clear yet which patients are more likely to respond to BCG.To evaluate the role of the methylation of 25 tumour suppressor genes (TSG) as clinical outcome predictive biomarkers in T1G3 bladder tumours treated with BCG.A retrospective design included 91 paraffin-embedded tumours of patients with T1G3 primary non-muscle-invasive disease undergoing nonmaintenance BCG treatment.The methylation status of 25 TSGs was measured using a methylation-specific multiplex ligation-dependent probe amplification (MS-MLPA) assay. Recurrence, progression into muscle-invasive tumours, and disease-specific survival (DSS) rates were analysed using univariate and multivariate tests.The genes most frequently methylated included STK11 (94.5%), MSH6 (81.3%), BRCA1 (72.5%), PAX5A (68.1%), MGMT (67.0%), CDH13 (62.6%), and IGSF4 (61.5%). Methylation was newly identified in T1G3 tumours for TP73, MSH6, ESR1, PAX5A, WT1, CD44, ATM, IGSF4, CHFR, BRCA2, THBS1, PYCARD, STK11, and GATA5. Methylation for several TSGs was significantly associated with multifocality and tumour size. Patients with different methylation statuses of TSGs showed differential recurrence rates (PAX6: p = 0.025), progression rates (MSH6: p = 0.040; RB1: p = 0.042; THBS1: p = 0.041; PYCARD: p = 0.048; TP73: p = 0.048; ESR1: p = 0.036; and GATA5: p = 0.019), and DSS rates (GATA5: p = 0.037). Several combinations improved prediction for progression. Multivariate analyses indicated that among the combinations remaining as independent predictors, two genes-MSH6 and THBS1-already provided the most significant predictive assessment for progression (p = 0.004). The major limitation of this study is related to its retrospective design.The methylation status of TSGs was associated with the clinical outcome of patients with T1G3 tumours undergoing BCG treatment under three clinical end points: recurrence, progression, and DSS. The methylation status of TSGs distinguished patients responding to BCG from those who may require a more aggressive therapeutic intervention." @default.
• W2078751312 created "2016-06-24" @default.
• W2078751312 creator A5033224206 @default.
• W2078751312 creator A5036848835 @default.
• W2078751312 creator A5045031134 @default.
• W2078751312 creator A5052620864 @default.
• W2078751312 creator A5065040377 @default.
• W2078751312 creator A5082719104 @default.
• W2078751312 date "2011-07-01" @default.
• W2078751312 modified "2023-10-17" @default.
• W2078751312 title "Evaluation of the Methylation Status of Tumour Suppressor Genes for Predicting Bacillus Calmette-Guérin Response in Patients With T1G3 High-Risk Bladder Tumours" @default.
• W2078751312 cites W1504303645 @default.
• W2078751312 cites W1976770439 @default.
• W2078751312 cites W1999628666 @default.
• W2078751312 cites W2029484950 @default.
• W2078751312 cites W2032777920 @default.
• W2078751312 cites W2036986058 @default.
• W2078751312 cites W2056035458 @default.
• W2078751312 cites W2061611574 @default.
• W2078751312 cites W2068990869 @default.
• W2078751312 cites W2078339963 @default.
• W2078751312 cites W2089548634 @default.
• W2078751312 cites W2092317370 @default.
• W2078751312 cites W2100812557 @default.
• W2078751312 cites W2105935489 @default.
• W2078751312 cites W2111107512 @default.
• W2078751312 cites W2111872185 @default.
• W2078751312 cites W2119938419 @default.
• W2078751312 cites W2124011381 @default.
• W2078751312 cites W2125228883 @default.
• W2078751312 cites W2129430629 @default.
• W2078751312 cites W2153887787 @default.
• W2078751312 cites W2154146769 @default.
• W2078751312 cites W2166174406 @default.
• W2078751312 cites W2169385429 @default.
• W2078751312 cites W2170358006 @default.
• W2078751312 cites W2171281008 @default.
• W2078751312 doi "https://doi.org/10.1016/j.eururo.2011.04.020" @default.
• W2078751312 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/21514719" @default.
• W2078751312 hasPublicationYear "2011" @default.
• W2078751312 type Work @default.
• W2078751312 sameAs 2078751312 @default.
• W2078751312 citedByCount "71" @default.
• W2078751312 countsByYear W20787513122012 @default.
• W2078751312 countsByYear W20787513122013 @default.
• W2078751312 countsByYear W20787513122014 @default.
• W2078751312 countsByYear W20787513122015 @default.
• W2078751312 countsByYear W20787513122016 @default.
• W2078751312 countsByYear W20787513122017 @default.
• W2078751312 countsByYear W20787513122018 @default.
• W2078751312 countsByYear W20787513122019 @default.
• W2078751312 countsByYear W20787513122020 @default.
• W2078751312 countsByYear W20787513122021 @default.
• W2078751312 countsByYear W20787513122022 @default.
• W2078751312 countsByYear W20787513122023 @default.
• W2078751312 crossrefType "journal-article" @default.
• W2078751312 hasAuthorship W2078751312A5033224206 @default.
• W2078751312 hasAuthorship W2078751312A5036848835 @default.
• W2078751312 hasAuthorship W2078751312A5045031134 @default.
• W2078751312 hasAuthorship W2078751312A5052620864 @default.
• W2078751312 hasAuthorship W2078751312A5065040377 @default.
• W2078751312 hasAuthorship W2078751312A5082719104 @default.
• W2078751312 hasConcept C104317684 @default.
• W2078751312 hasConcept C121608353 @default.
• W2078751312 hasConcept C126322002 @default.
• W2078751312 hasConcept C143998085 @default.
• W2078751312 hasConcept C2780352672 @default.
• W2078751312 hasConcept C33288867 @default.
• W2078751312 hasConcept C502942594 @default.
• W2078751312 hasConcept C55493867 @default.
• W2078751312 hasConcept C71924100 @default.
• W2078751312 hasConcept C86803240 @default.
• W2078751312 hasConceptScore W2078751312C104317684 @default.
• W2078751312 hasConceptScore W2078751312C121608353 @default.
• W2078751312 hasConceptScore W2078751312C126322002 @default.
• W2078751312 hasConceptScore W2078751312C143998085 @default.
• W2078751312 hasConceptScore W2078751312C2780352672 @default.
• W2078751312 hasConceptScore W2078751312C33288867 @default.
• W2078751312 hasConceptScore W2078751312C502942594 @default.
• W2078751312 hasConceptScore W2078751312C55493867 @default.
• W2078751312 hasConceptScore W2078751312C71924100 @default.
• W2078751312 hasConceptScore W2078751312C86803240 @default.
• W2078751312 hasIssue "1" @default.
• W2078751312 hasLocation W20787513121 @default.
• W2078751312 hasLocation W20787513122 @default.
• W2078751312 hasOpenAccess W2078751312 @default.
• W2078751312 hasPrimaryLocation W20787513121 @default.
• W2078751312 hasRelatedWork W1411054225 @default.
• W2078751312 hasRelatedWork W1979321249 @default.
• W2078751312 hasRelatedWork W2348170098 @default.
• W2078751312 hasRelatedWork W2392691312 @default.
• W2078751312 hasRelatedWork W2415761310 @default.
• W2078751312 hasRelatedWork W2472744187 @default.
• W2078751312 hasRelatedWork W2474195589 @default.
• W2078751312 hasRelatedWork W2588553988 @default.
• W2078751312 hasRelatedWork W2118673085 @default.
• W2078751312 hasRelatedWork W3030110517 @default.
• W2078751312 hasVolume "60" @default.

• next